Member Info for x54v

Seems that Chris Akers has taken the placing.

https://twitter.com/sportschris/status/1230750822494945282

There have been some major moves up following announcements of his involvement in other stocks recently e.g. ASLR and DEV.

The potential for something similar here perhaps when his TR-1 is announced shortly.

32:31 "I'm going to be doing a lot of investor relations every second week. I can't do that without newsflow"

https://www.valuethemarkets.com/2020/02/12/video-open-orphans-cathal-friel-details-ambitions-2020-plans-following-5-3m-raise-in-exclusive-presentation-orph/

Some chunkier buys today. Loading up for contract news next week perhaps.

536079 @ 6.003 and 819672 @ 6.1.

New presentation just released today.

"The market for a range of safer chemotherapies, that are proprietary to Avacta, is expected to be multiples of the current chemotherapy market size because patients can be treated for longer and a wider group of patients will be eligible."

"A safer form of doxorubicin would permit more cycles of treatment per patient, and use of the drug with older patients with heart problems, so the market for AVA6000 pro-doxorubicin is expected to be several $bn."

https://avacta.com/wp-content/uploads/2020/02/Avacta-Investor-Presentation-February-2020-converted.pdf

Good reply from Nobbygnome on the other BB to that one:

"The whole point is that the new management have reduced the costs massively and so now it is close to profitability. When I was at the investment show last week, I made precisely your point. Cathal muttered about the scandal of Aim and rummaged into a file to produce a spreadsheet showing all the salaries of the HVIVO employees, when they took the company over. The Board and top managers were paid truly ridiculous amounts and Cathal proudly said 'they have all gone'. Yes I know that is hard to believe but that is exactly what happened. There was another investor standing next to me so if he reads this board he can corroborate the story.

That is a major reason why HVIVO is now close to profit"

Miles McNulty clearly of the view that the potential share price appreciation here could be life changing.

"#AVCT: see my Tweets. Reasonable chance of 20x by end 2021."

https://twitter.com/MylesMcNulty/status/1229716209022775297

Market cap currently £32m vs...

"So, @hVIVO_UK has a very extensive asset portfolio valued at over £50m that it brings into the Orphan Family.

No other challenge study service provider has such a comprehensive portfolio, making it a world leader in the provision of virology & vaccine challenge study services."

https://twitter.com/OpenOrphan/status/1229670989342085121

Excellent video posted here by Stockonomist highlighting what investors can expect shortly:

https://twitter.com/Stockonomist/status/1227518115300478976

"There is 2 to 5x valuation by being in the clinical stages compared with where we currently are. So, a significant valuation uplift likely as we move the Affimers into the clinic"

And from the January trading update:

"We are also due to take our first drug AVA6000, a re-engineered form of the chemotherapy Doxorubicin into the clinic in the middle of 2020, making it a ground-breaking year for the Group."

"I am therefore looking ahead with confidence and believe 2020 will be an exciting year of further progress."

https://investegate.co.uk/avacta-group-plc--avct-/rns/trading-update/202001230700046434A/

Newsflow this year has been very positive so far. Here's a quick reminder.

3rd Feb - Avacta and Daewoong Agreement

"The potential for AffyXell's new class of cell therapies, which can be applied to a wide range of inflammatory and autoimmune diseases, is enormous."

"We believe that this has the potential to create substantial value for stakeholders in the near future."

https://investegate.co.uk/avacta-group-plc--avct-/rns/avacta-and-daewoong-agreement/202002030700106520B/

28th Jan - Successful initial proof-of-concept

"These in vivo efficacy and distribution data demonstrate initial proof-of-concept for TMAC drug conjugates and represent an important milestone for the Company."

"We continue to receive significant commercial interest in the TMAC concept"

"This is hugely encouraging for the TMAC programme"

https://investegate.co.uk/avacta-group-plc--avct-/rns/successful-initial-proof-of-concept/202001280700130774B/

23rd Jan - Trading Update

"Revenues for the period, which include the initial milestone payment from LG Chem, have grown 100% to £5.5m from £2.76m (12 months ended 31 July 2018) and are ahead of market expectations."

"Importantly revenues from the Affimer® diagnostics business have grown by 130% as more customer evaluations of the Affimer® platform are underway."

"The Group's order intake and sales pipeline into 2020 are the strongest to date."

"The cash position at 31 December 2019 was £8.7m (31 July 2018: £5.2m), also ahead of market forecasts"

"I am therefore looking ahead with confidence and believe 2020 will be an exciting year of further progress."

https://investegate.co.uk/avacta-group-plc--avct-/rns/trading-update/202001230700046434A/

8th Jan - Avacta and Daewoong Establish Joint Venture

"Cell and gene therapies are attracting intense clinical and commercial interest. We are very excited to establish this joint venture with Daewoong, one of the top pharmaceutical companies in Korea, to develop the Affimer platform in this important therapeutic area. Our vision is to combine our platforms to create the next generation of cell therapies, for which the potential is huge. "

https://investegate.co.uk/avacta-group-plc--avct-/rns/avacta-and-daewoong-establish-joint-venture/202001080700051128Z/

27:53 - "People coming in today should look at getting 2 to 3 times their money by Christmas when we exit."

31:29 "We need to demonstrate at least 3 or 4 large contract conversions in the coming months, one hopefully next week, one the following month..."

32:18 "And next week we hope to let's say drive things forward and keep it going."

32:31 "I'm going to be doing a lot of investor relations every second week. I can't do that without newsflow."

49:24 "I would be disappointed if in the coming week or two there's not some decent newsflow from either Open Orphan (Venn side) or Hvivo (contract wins). So I would guide people watch the market for newsflow and contract wins and watch what happens to the share price afterwards."

49:42 "I think short term over the coming days and weeks, I'm not going to get obsessed if the share price is up or down 10%. I'm looking for the double when we get rerated in a month or two and a triple by the year end."

51:15 "This is a sleeping giant. It's probably one of the best opportunities I've ever seen in my life. And given that we're in control and we've got a clear plan to fix it and sell it, I think it's great."

https://tinyurl.com/v4mvjgj

Myles McNulty continuing to load up by the looks of it. Now at 0.9% of the company. Some real conviction buying here.

"Holding ~0.9% of #AVCT now, across family. Assuming success in both the pro-Dox (2020) and the PD-L1 (2021) Phase I trials, I think it could hit £1bn mkt cap by end next year.

Success in the first TMAC drug trial (2022) will see the Co acquired for multiple billions, I think."

https://twitter.com/MylesMcNulty/status/1228009226691325954

Can currently be bought at the 45p placing price where directors invested £2 million of their own money and 2 instis loaded heavily.

Strong potential upside from here to the 130p Arden target price. Nearly triple your money.

"We set our target price at 130p, a 10x FY21 P/E multiple, 1.1x EV/Sales and 9.1x EV/EBIT"

Institutions keen to buy at 45p as well.

River & Mercantile buying 6.48% of the company and Ruffer moving up to 11% of the company.

https://investegate.co.uk/ince-group-plc--the---ince-/rns/holding-s--in-company/202002041802069668B

Clearly they are happy with a 45p entry price and see good upside from here.

https://investegate.co.uk/ince-group-plc--the---ince-/rns/holding-s--in-company/202002101156355074C

Directors happy to buy over £2 million worth of shares between them at 45p.

Not a token £10k or £50k, but over £2 million.

You're only going to buy so heavily if you think there's a seriously large return to be made.

https://investegate.co.uk/ince-group-plc--the---ince-/rns/pdmr-and-aim-rule-17-notifications/202002041455269509B

Yes, under the radar, excellent prospects, and you can still buy the shares cheaper than the 6.1p CF paid for £300k worth in the placing.

A bargain at this level, especially given CF has hinted that shareholders can expect a 2x or 3x return on their money by the end of the year.

Bullish note. Target price: 130p vs the current 45.3p

"An outstanding opportunity – Rarely are investors afforded the opportunity to participate in the shares of a company at such a discounted valuation, despite robust ongoing operations. We believe Ince, at this time, represents one of those opportunities."

27:53 - "People coming in today should look at getting 2 to 3 times their money by Christmas when we exit."

https://tinyurl.com/v4mvjgj

https://www.valuethemarkets.com/2020/02/12/argo-blockchain-poised-to-boom-as-bitcoin-breaks-10000-arb/

Q&A with Open Orphan’s #ORPH Cathal Friel

https://tinyurl.com/tv6rv99

https://investegate.co.uk/open-orphan-plc--orph-/rns/upcoming-investor-events/202002060700121216C/